Myelodysplastic Syndrome - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 784 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Myelodysplastic Syndrome - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Myelodysplastic Syndrome - Pipeline Review, H1 2016', provides an overview of the Myelodysplastic Syndrome pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome
- The report reviews pipeline therapeutics for Myelodysplastic Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Myelodysplastic Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Myelodysplastic Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Myelodysplastic Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Myelodysplastic Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
Introduction 7
Myelodysplastic Syndrome Overview 8
Therapeutics Development 9
Myelodysplastic Syndrome - Therapeutics under Development by Companies 11
Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes 18
Myelodysplastic Syndrome - Pipeline Products Glance 19
Myelodysplastic Syndrome - Products under Development by Companies 22
Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes 31
Myelodysplastic Syndrome - Companies Involved in Therapeutics Development 32
Myelodysplastic Syndrome - Therapeutics Assessment 124
Drug Profiles 146
Myelodysplastic Syndrome - Recent Pipeline Updates 467
Myelodysplastic Syndrome - Dormant Projects 752
Myelodysplastic Syndrome - Discontinued Products 758
Myelodysplastic Syndrome - Product Development Milestones 760
Appendix 767

List of Tables

Number of Products under Development for Myelodysplastic Syndrome, H1 2016 25
Number of Products under Development for Myelodysplastic Syndrome - Comparative Analysis, H1 2016 26
Number of Products under Development by Companies, H1 2016 27
Number of Products under Development by Companies, H1 2016 (Contd..1) 28
Number of Products under Development by Companies, H1 2016 (Contd..2) 29
Number of Products under Development by Companies, H1 2016 (Contd..3) 30
Number of Products under Development by Companies, H1 2016 (Contd..4) 31
Number of Products under Development by Companies, H1 2016 (Contd..5) 32
Number of Products under Development by Companies, H1 2016 (Contd..6) 33
Number of Products under Investigation by Universities/Institutes, H1 2016 34
Comparative Analysis by Late Stage Development, H1 2016 35
Comparative Analysis by Clinical Stage Development, H1 2016 36
Comparative Analysis by Early Stage Development, H1 2016 37
Products under Development by Companies, H1 2016 38
Products under Development by Companies, H1 2016 (Contd..1) 39
Products under Development by Companies, H1 2016 (Contd..2) 40
Products under Development by Companies, H1 2016 (Contd..3) 41
Products under Development by Companies, H1 2016 (Contd..4) 42
Products under Development by Companies, H1 2016 (Contd..5) 43
Products under Development by Companies, H1 2016 (Contd..6) 44
Products under Development by Companies, H1 2016 (Contd..7) 45
Products under Development by Companies, H1 2016 (Contd..8) 46
Products under Investigation by Universities/Institutes, H1 2016 47
Myelodysplastic Syndrome - Pipeline by 4SC AG, H1 2016 48
Myelodysplastic Syndrome - Pipeline by Acceleron Pharma, Inc., H1 2016 49
Myelodysplastic Syndrome - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 50
Myelodysplastic Syndrome - Pipeline by Aeglea BioTherapeutics, Inc., H1 2016 51
Myelodysplastic Syndrome - Pipeline by Agios Pharmaceuticals, Inc., H1 2016 52
Myelodysplastic Syndrome - Pipeline by Altor BioScience Corporation, H1 2016 53
Myelodysplastic Syndrome - Pipeline by Amgen Inc., H1 2016 54
Myelodysplastic Syndrome - Pipeline by Apogenix GmbH, H1 2016 55
Myelodysplastic Syndrome - Pipeline by Arno Therapeutics, Inc., H1 2016 56
Myelodysplastic Syndrome - Pipeline by Arog Pharmaceuticals, Inc., H1 2016 57
Myelodysplastic Syndrome - Pipeline by Array BioPharma Inc., H1 2016 58
Myelodysplastic Syndrome - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 59
Myelodysplastic Syndrome - Pipeline by Atara Biotherapeutics, Inc., H1 2016 60
Myelodysplastic Syndrome - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 61
Myelodysplastic Syndrome - Pipeline by Bio-Path Holdings, Inc., H1 2016 62
Myelodysplastic Syndrome - Pipeline by BioLineRx, Ltd., H1 2016 63
Myelodysplastic Syndrome - Pipeline by BioLite, Inc., H1 2016 64
Myelodysplastic Syndrome - Pipeline by Boehringer Ingelheim GmbH, H1 2016 65
Myelodysplastic Syndrome - Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2016 66
Myelodysplastic Syndrome - Pipeline by Boston Biomedical, Inc., H1 2016 67
Myelodysplastic Syndrome - Pipeline by Bristol-Myers Squibb Company, H1 2016 68
Myelodysplastic Syndrome - Pipeline by Cantex Pharmaceuticals, Inc., H1 2016 69
Myelodysplastic Syndrome - Pipeline by Celator Pharmaceuticals, Inc., H1 2016 70
Myelodysplastic Syndrome - Pipeline by Celgene Corporation, H1 2016 71
Myelodysplastic Syndrome - Pipeline by Celldex Therapeutics, Inc., H1 2016 72
Myelodysplastic Syndrome - Pipeline by Cellerant Therapeutics, Inc., H1 2016 73
Myelodysplastic Syndrome - Pipeline by Celyad SA, H1 2016 74
Myelodysplastic Syndrome - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016 75
Myelodysplastic Syndrome - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016 76
Myelodysplastic Syndrome - Pipeline by CrystalGenomics, Inc., H1 2016 77
Myelodysplastic Syndrome - Pipeline by CTI BioPharma Corp., H1 2016 78
Myelodysplastic Syndrome - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 79
Myelodysplastic Syndrome - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 80
Myelodysplastic Syndrome - Pipeline by DiNonA Inc., H1 2016 81
Myelodysplastic Syndrome - Pipeline by Eisai Co., Ltd., H1 2016 82
Myelodysplastic Syndrome - Pipeline by Eleos Inc., H1 2016 83
Myelodysplastic Syndrome - Pipeline by Eli Lilly and Company, H1 2016 84
Myelodysplastic Syndrome - Pipeline by EpiZyme, Inc., H1 2016 85
Myelodysplastic Syndrome - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 86
Myelodysplastic Syndrome - Pipeline by FORMA Therapeutics, Inc., H1 2016 87
Myelodysplastic Syndrome - Pipeline by Fujifilm Corporation, H1 2016 88
Myelodysplastic Syndrome - Pipeline by H3 Biomedicine Inc., H1 2016 89
Myelodysplastic Syndrome - Pipeline by IGF Oncology, LLC., H1 2016 90
Myelodysplastic Syndrome - Pipeline by ImmunoGen, Inc., H1 2016 91
Myelodysplastic Syndrome - Pipeline by Incyte Corporation, H1 2016 92
Myelodysplastic Syndrome - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2016 93
Myelodysplastic Syndrome - Pipeline by Johnson & Johnson, H1 2016 94
Myelodysplastic Syndrome - Pipeline by Juno Therapeutics Inc., H1 2016 95
Myelodysplastic Syndrome - Pipeline by JW Pharmaceutical Corporation, H1 2016 96
Myelodysplastic Syndrome - Pipeline by Kainos Medicine, Inc., H1 2016 97
Myelodysplastic Syndrome - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016 98
Myelodysplastic Syndrome - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 99
Myelodysplastic Syndrome - Pipeline by Kiadis Pharma B.V., H1 2016 100
Myelodysplastic Syndrome - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 101
Myelodysplastic Syndrome - Pipeline by La Jolla Pharmaceutical Company, H1 2016 102
Myelodysplastic Syndrome - Pipeline by Les Laboratoires Servier SAS, H1 2016 103
Myelodysplastic Syndrome - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016 104
Myelodysplastic Syndrome - Pipeline by MacroGenics, Inc., H1 2016 105
Myelodysplastic Syndrome - Pipeline by medac GmbH, H1 2016 106
Myelodysplastic Syndrome - Pipeline by MedImmune, LLC, H1 2016 107
Myelodysplastic Syndrome - Pipeline by MEI Pharma, Inc., H1 2016 108
Myelodysplastic Syndrome - Pipeline by Merck & Co., Inc., H1 2016 109
Myelodysplastic Syndrome - Pipeline by Merus B.V., H1 2016 110
Myelodysplastic Syndrome - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 111
Myelodysplastic Syndrome - Pipeline by Mirati Therapeutics Inc., H1 2016 112
Myelodysplastic Syndrome - Pipeline by Mirna Therapeutics, Inc., H1 2016 113
Myelodysplastic Syndrome - Pipeline by Nemucore Medical Innovations, Inc., H1 2016 114
Myelodysplastic Syndrome - Pipeline by Novartis AG, H1 2016 115
Myelodysplastic Syndrome - Pipeline by Onconova Therapeutics, Inc., H1 2016 116
Myelodysplastic Syndrome - Pipeline by Opsona Therapeutics Limited, H1 2016 117
Myelodysplastic Syndrome - Pipeline by OXiGENE, Inc., H1 2016 118
Myelodysplastic Syndrome - Pipeline by Pfizer Inc., H1 2016 119
Myelodysplastic Syndrome - Pipeline by Pharma Mar, S.A., H1 2016 120
Myelodysplastic Syndrome - Pipeline by Plexxikon Inc., H1 2016 121
Myelodysplastic Syndrome - Pipeline by Polyphor Ltd., H1 2016 122
Myelodysplastic Syndrome - Pipeline by Regen BioPharma, Inc., H1 2016 123
Myelodysplastic Syndrome - Pipeline by Rich Pharmaceuticals, Inc., H1 2016 124
Myelodysplastic Syndrome - Pipeline by Seattle Genetics, Inc., H1 2016 125
Myelodysplastic Syndrome - Pipeline by Stemline Therapeutics, Inc., H1 2016 126
Myelodysplastic Syndrome - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 127
Myelodysplastic Syndrome - Pipeline by Sunesis Pharmaceuticals, Inc., H1 2016 128
Myelodysplastic Syndrome - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016 129
Myelodysplastic Syndrome - Pipeline by Synta Pharmaceuticals Corp., H1 2016 130
Myelodysplastic Syndrome - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 131
Myelodysplastic Syndrome - Pipeline by Targazyme, Inc., H1 2016 132
Myelodysplastic Syndrome - Pipeline by TetraLogic Pharmaceuticals, H1 2016 133
Myelodysplastic Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 134
Myelodysplastic Syndrome - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 135
Myelodysplastic Syndrome - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H1 2016 136
Myelodysplastic Syndrome - Pipeline by Tolero Pharmaceuticals, Inc., H1 2016 137
Myelodysplastic Syndrome - Pipeline by Tragara Pharmaceuticals, Inc., H1 2016 138
Myelodysplastic Syndrome - Pipeline by Trillium Therapeutics Inc., H1 2016 139
Assessment by Monotherapy Products, H1 2016 140
Assessment by Combination Products, H1 2016 141
Number of Products by Stage and Target, H1 2016 143
Number of Products by Stage and Mechanism of Action, H1 2016 152
Number of Products by Stage and Route of Administration, H1 2016 159
Number of Products by Stage and Molecule Type, H1 2016 161
Myelodysplastic Syndrome Therapeutics - Recent Pipeline Updates, H1 2016 483
Myelodysplastic Syndrome - Dormant Projects, H1 2016 768
Myelodysplastic Syndrome - Dormant Projects (Contd..1), H1 2016 769
Myelodysplastic Syndrome - Dormant Projects (Contd..2), H1 2016 770
Myelodysplastic Syndrome - Dormant Projects (Contd..3), H1 2016 771
Myelodysplastic Syndrome - Dormant Projects (Contd..4), H1 2016 772
Myelodysplastic Syndrome - Dormant Projects (Contd..5), H1 2016 773
Myelodysplastic Syndrome - Discontinued Products, H1 2016 774
Myelodysplastic Syndrome - Discontinued Products (Contd..1), H1 2016 775